Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALVOVAR trial in poor-prognosis ovarian cancer
2023-508260-30-01Phase 3Authorised
- Sponsor
- Arcagy-Gineco
- Start
- May 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel, filgrastim and bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Arcagy-Gineco. Primary endpoints: Late complete debulking surgery rate and Overall survival. Planned start May 2024; status: authorised.
02
Drugs
carboplatinpaclitaxelfilgrastimbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2023-508260-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508260-30-01.